View attachment 36736 Rick Doblin, the founder and president of MAPS, said this in a recent “Ask Me Anything” interview on Reddit:
We’ve just completed the world’s first study of the therapeutic use of LSD in over 40 years, in Switzerland to treat anxiety associated with end-of-life issues. Eleven of the 12 subjects had never done LSD before and there were no serious adverse events, even in people facing death.
This recently completed Swiss study is truly momentous — it’s the first “double-blind, placebo-controlled investigation of LSD-assisted psychotherapy since the early 1970s.” This pilot study found that two LSD-assisted psychotherapy sessions successfully reduced anxiety in end-of-life patients. The study was led by Peter Gasser, M.D., who wrote a letter (PDF) to friends and colleagues at its completion. In it he writes that “all the 12 participants reported a benefit from the treatment.” He continues:
I am proud to say that we had in 30 sessions (22 with full dose 200 μg LSD and 8 with placebo dose 20 μg LSD) no severe side effects such as psychotic experiences or suicidal crisis or flashbacks or severe anxieties (bad trips)…That means that we can show that LSD treatment can be safe when it is done in a carefully controlled clinical setting.
The paper, which was completed in August and accepted for publication in the peer-reviewed Journal of Nervous and Mental Disease in December, makes these conclusions:
You can read the full results of the study in this clinical report. After a long hiatus, this promising study should pave the way to continued interest and research regarding psychedelic-assisted therapy. If you want to support this kind of research, consider donating to MAPS.
- This pilot study found positive trends in the reduction of anxiety following two LSD-assisted psychotherapy sessions.
- Anxiety remained at reduced levels at 12-month follow-up sessions, implying durability of effects.
- LSD-assisted psychotherapy can be safely administered in these subjects.
- The results of this small pilot study are promising, and should be pursued in larger samples.
13 January 2014
The clinical report is attached below, if anyone is interested.
Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.